1. Home
  2. CDT vs NSRX Comparison

CDT vs NSRX Comparison

Compare CDT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.26

Market Cap

22.1M

Sector

Health Care

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$2.65

Market Cap

25.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDT
NSRX
Founded
2019
2019
Country
United States
Israel
Employees
6
7
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.1M
25.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CDT
NSRX
Price
$1.26
$2.65
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
32.9K
126.7K
Earning Date
04-15-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$1.98
52 Week High
$11.00
$9.99

Technical Indicators

Market Signals
Indicator
CDT
NSRX
Relative Strength Index (RSI) 35.23 47.00
Support Level $1.24 $2.04
Resistance Level $1.66 $3.48
Average True Range (ATR) 0.22 0.28
MACD -0.09 -0.01
Stochastic Oscillator 8.21 27.60

Price Performance

Historical Comparison
CDT
NSRX

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: